214 related articles for article (PubMed ID: 15548440)
1. Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care.
Saad F; Olsson C; Schulman CC
Eur Urol; 2004 Dec; 46(6):731-39; discussion 739-40. PubMed ID: 15548440
[TBL] [Abstract][Full Text] [Related]
2. Bone health in men with prostate cancer: diagnostic and therapeutic considerations.
Saad F; Perrotte P; Bénard F; McCormack M; Karakiewicz PI
Can J Urol; 2005 Jun; 12 Suppl 2():9-15. PubMed ID: 16018826
[TBL] [Abstract][Full Text] [Related]
3. Bone loss in prostate cancer: evaluation, treatment and prevention.
Saad F
Can J Urol; 2005 Feb; 12 Suppl 1():71-6; discussion 99-100. PubMed ID: 15780171
[TBL] [Abstract][Full Text] [Related]
4. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
Higano CS
Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
[TBL] [Abstract][Full Text] [Related]
5. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis.
Saad F; McKiernan J; Eastham J
Urol Oncol; 2006; 24(1):4-12. PubMed ID: 16414486
[TBL] [Abstract][Full Text] [Related]
6. Multidisciplinary management of bone complications in prostate cancer and optimizing outcomes of bisphosphonate therapy.
Saad F; Sternberg CN
Nat Clin Pract Urol; 2007 Feb; 4 Suppl 1():S3-13. PubMed ID: 17264863
[TBL] [Abstract][Full Text] [Related]
7. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy.
Israeli RS; Ryan CW; Jung LL
J Urol; 2008 Feb; 179(2):414-23. PubMed ID: 18076933
[TBL] [Abstract][Full Text] [Related]
8. Preservation of bone health in prostate cancer.
Lattouf JB; Saad F
Curr Opin Support Palliat Care; 2007 Oct; 1(3):192-7. PubMed ID: 18685362
[TBL] [Abstract][Full Text] [Related]
9. Bone health in men receiving androgen deprivation therapy for prostate cancer.
Eastham JA
J Urol; 2007 Jan; 177(1):17-24. PubMed ID: 17161994
[TBL] [Abstract][Full Text] [Related]
10. Natural history and treatment of bone complications in prostate cancer.
Saad F; Clarke N; Colombel M
Eur Urol; 2006 Mar; 49(3):429-40. PubMed ID: 16431012
[TBL] [Abstract][Full Text] [Related]
11. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
Wilcox A; Carnes ML; Moon TD; Tobias R; Baade H; Stamos E; Elliott ME
Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
[TBL] [Abstract][Full Text] [Related]
12. Bone-directed treatments for prostate cancer.
Saad F
Hematol Oncol Clin North Am; 2006 Aug; 20(4):947-63. PubMed ID: 16861125
[TBL] [Abstract][Full Text] [Related]
13. Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates.
Green JR
Acta Oncol; 2005; 44(3):282-92. PubMed ID: 16076701
[TBL] [Abstract][Full Text] [Related]
14. The role of bisphosphonates in the management of bone metastases in prostate cancer.
Saad F; Chi K; Fleshner N
Can J Urol; 2004 Oct; 11(5):2376-82. PubMed ID: 15576002
[TBL] [Abstract][Full Text] [Related]
15. Optimal management of metastatic bone disease.
Major P
Eur J Oncol Nurs; 2007; 11 Suppl 2():S32-7. PubMed ID: 17804294
[TBL] [Abstract][Full Text] [Related]
16. Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues.
Gomella LG
BJU Int; 2007 Jan; 99 Suppl 1():25-9; discussion 30. PubMed ID: 17229166
[TBL] [Abstract][Full Text] [Related]
17. New generation of bisphosphonates: broad clinical utility in breast and prostate cancer.
Rosen LS
Oncology (Williston Park); 2004 May; 18(5 Suppl 3):26-32. PubMed ID: 15202585
[TBL] [Abstract][Full Text] [Related]
18. Quality of life in patients with skeletal metastases of prostate cancer and status prior to start of endocrine therapy: results from the Scandinavian Prostate Cancer Group Study 5.
Jønler M; Nielsen OS; Groenvold M; Hedlund PO; Damber L; Hedelin H; Waldén M;
Scand J Urol Nephrol; 2005; 39(1):42-8. PubMed ID: 15764270
[TBL] [Abstract][Full Text] [Related]
19. Maintaining bone health in prostate cancer throughout the disease continuum.
Saad F; Eastham J
Semin Oncol; 2010 Jun; 37 Suppl 1():S30-7. PubMed ID: 20682370
[TBL] [Abstract][Full Text] [Related]
20. Management of the spectrum of hormone refractory prostate cancer.
Clarke NW
Eur Urol; 2006 Sep; 50(3):428-38; discussion 438-9. PubMed ID: 16797118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]